Symptomatic Patient With Endemic-Region Exposure
Covered when the individual has symptoms of Lyme disease and plausible geographic exposure.
ALL of the following
Symptoms consistent with Lyme disease.
History of travel to or residence in a region endemic for Lyme disease, with or without a known tick bite.
Serologic testing uses a two-tier strategy: a sensitive enzyme immunoassay (EIA) or immunofluorescence assay (IFA), followed by a western immunoblot or an FDA-cleared second EIA assay.
Cardiac or Neurologic Presentation With Endemic-Region Exposure
Covered when there is plausible endemic-region exposure and a compatible cardiac or neurologic presentation.
ALL of the following
History of travel to or residence in a region endemic for Lyme disease.
ONE or more of the following clinical presentations
Acute myocarditis or pericarditis of unknown cause.
Meningitis, encephalitis, or myelitis.
Painful radiculoneuritis.
Mononeuropathy multiplex, including confluent mononeuropathy multiplex.
Acute cranial neuropathy, particularly cranial nerve VII or VIII and less commonly III, V, VI, or other cranial nerves.
Standard and Modified Two-Tier Serologic Testing
Use the standard or modified two-tier serologic algorithm for covered Lyme disease testing.
ALL of the following steps
Perform a first-tier EIA or IFA to detect antibodies to Borrelia burgdorferi.
If the first-tier result is negative, consider the patient seronegative and do not perform further testing on that specimen.
If the first-tier result is positive, equivocal, or indeterminate, perform second-tier testing.
ONE of the following second-tier options
Standard two-tier testing with a western immunoblot.
Modified two-tier testing with an EIA specifically cleared by the FDA for use as the second-tier confirmatory test.
Clinical Indications for Testing
Testing is appropriate when compatible clinical findings are accompanied by plausible epidemiologic exposure and is not intended as nonspecific screening.
ALL of the following
Clinical findings are compatible with Lyme disease, including an acute neurologic syndrome, acute myocarditis or pericarditis of unknown cause, or compatible Lyme arthritis manifestations such as brief attacks of arthralgia or intermittent or persistent arthritis in one or a few large joints, especially the knee.
There is epidemiologically plausible exposure to ticks infected with B. burgdorferi, including residence in or travel to an endemic area.
Presentation-Specific Test Selection
Select testing based on the clinical presentation and use validated, FDA-cleared or guideline-supported methods.
ONE of the following presentation-specific pathways
ALL of the following
Typical erythema migrans lesion in a patient with plausible tick exposure.
Make a clinical diagnosis rather than laboratory testing.
ALL of the following
A skin lesion suggestive of but atypical for erythema migrans.
Perform antibody testing on an acute-phase serum sample; if negative, obtain a convalescent-phase serum sample at least 2–3 weeks later.
COVERAGE CRITERIA — DOES NOT MEET: Serologic testing for individuals with an erythema migrans rash. Patients with a rash clinically consistent with erythema migrans who live in or recently traveled to an endemic area should be treated clinically for Lyme disease.
Serologic testing to screen asymptomatic patients living in endemic areas or following an Ixodes tick bite does not meet coverage criteria.
Serologic testing for nonspecific symptoms alone, including fatigue, myalgias, arthralgias, diffuse arthralgias, myalgias, or fibromyalgia, does not meet coverage criteria.
Routine testing does not meet coverage criteria for typical amyotrophic lateral sclerosis, relapsing-remitting multiple sclerosis, Parkinson's disease, dementia or cognitive decline, new-onset seizures, psychiatric illness, or developmental, behavioral, or psychiatric disorders in children.
Routine testing does not meet coverage criteria for chronic cardiomyopathy of unknown cause, nonspecific brain white-matter MRI abnormalities without other clinical or epidemiologic support, or neurologic syndromes not listed above without other clinical or epidemiologic support.
COVERAGE CRITERIA — DOES NOT MEET: Detection of Borrelia burgdorferi by nucleic acid identification techniques, including direct or amplified probe methods, does not meet coverage criteria.
Testing an individual removed tick for B. burgdorferi does not meet coverage criteria. Tick species identification may be submitted for guidance, but testing the tick for B. burgdorferi does not reliably predict clinical infection.
COVERAGE CRITERIA — DOES NOT MEET: All other testing for Borrelia burgdorferi not specifically described in the covered criteria does not meet coverage criteria.
COVERAGE CRITERIA — DOES NOT MEET: Do not routinely test asymptomatic patients after a tick bite or other potential exposure. Testing removed ticks does not predict whether the individual will develop infection.
Patients with typical erythema migrans should receive a clinical diagnosis and treatment rather than laboratory testing. For lesions atypical for erythema migrans, use acute-phase antibody testing followed by convalescent-phase testing if initially negative; use antibody testing rather than currently available direct detection methods such as PCR or culture of blood or skin.
COVERAGE CRITERIA — DOES NOT MEET: Do not order a western immunoblot as the initial test, when the first-tier EIA or IFA is negative, or without a preceding EIA or IFA, because specificity is diminished when immunoblot testing is performed alone.
An IgM immunoblot is useful only during the first 4 weeks after symptom onset. Disregard, or do not order when possible, a positive IgM result in patients with symptoms lasting longer than 4 weeks or with symptoms consistent with late Lyme disease; false-positive IgM results are common in these settings.
COVERAGE CRITERIA — DOES NOT MEET: Urine tests for B. burgdorferi, CD57 assays, novel culture techniques, and antibody panels that differ from standardized two-tier testing are not appropriate diagnostic tests and do not meet coverage criteria. These tests are not FDA cleared or lack sufficient validity and specificity.
COVERAGE CRITERIA — DOES NOT MEET: Other Lyme disease testing without sufficient published scientific support confirming that the test is required and beneficial for diagnosis or treatment does not meet coverage criteria.
COVERAGE CRITERIA — DOES NOT MEET: Repeat antibody testing in individuals who previously tested positive for Lyme disease is not medically necessary. Antibodies may persist for many years after successful treatment and should not be repeated to document cure or assess treatment response.
COVERAGE CRITERIA — DOES NOT MEET: Routine blood PCR is not recommended because its role is not well established and results are usually negative in early and late disease.
Routine CSF PCR or culture does not meet coverage criteria; yield of CSF PCR in neuroborreliosis is too low to exclude the diagnosis. When CSF testing is performed for suspected central nervous system neuroborreliosis, use simultaneous CSF and serum antibody testing with a validated CSF:serum antibody index, not CSF serology alone.
For possible Lyme arthritis, use serum antibody testing rather than blood or synovial fluid/tissue PCR or culture. In a seropositive patient requiring additional diagnostic specificity, synovial fluid or tissue PCR may be used rather than Borrelia culture.